QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05 Frankfurt time 21:05 London time 16:05 New York time.
Conference call date time: Wednesday, November 5, at 15:30 Frankfurt time 14:30 London time 09:30 New York time.
Three options for joining the conference call
Register for call back connection -Click here:Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2480
Conference ID: 3763132
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast -Click here:Access Webcast
A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1709559&tp_key=263df2a108
ContactIR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.
category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013673777/en/
Contacts:
John Gilardi
Vice President Head of Corporate Communications
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com
Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com
